Last reviewed · How we verify
Cibacalcin — Competitive Intelligence Brief
marketed
calcitonin (human synthetic)
Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1
Hematology
Recombinant protein
Live · refreshed every 30 min
Target snapshot
Cibacalcin (CALCITONIN HUMAN) — Novartis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cibacalcin TARGET | CALCITONIN HUMAN | Novartis | marketed | calcitonin (human synthetic) | Amylin receptor AMY2, Calcitonin receptor, Amylin receptor AMY1 | 1986-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (calcitonin (human synthetic) class)
- Novartis · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cibacalcin CI watch — RSS
- Cibacalcin CI watch — Atom
- Cibacalcin CI watch — JSON
- Cibacalcin alone — RSS
- Whole calcitonin (human synthetic) class — RSS
Cite this brief
Drug Landscape (2026). Cibacalcin — Competitive Intelligence Brief. https://druglandscape.com/ci/calcitonin-human. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing